8th Joint Americas Committee and European Committee for Treatment and Research in MS (ACTRIMS-ECTRIMS) meeting, Virtual Congress, 11-13 September 2020.
The following summarizes some of the highlights from Day 2 of ACTRIMS-ECTRIMS 2020.
September 26 Edition (special session on COVID-19)
September 13 Edition
September 11 Edition
8th Joint Americas Committee and European Committee for Treatment and Research in MS (ACTRIMS-ECTRIMS) meeting, Virtual Congress, 11-13 September 2020.
The following summarizes some of the highlights from Day 1 of ACTRIMS-ECTRIMS 2020.
September 26 Edition (special session on COVID-19)
September 13 Edition
September 12 EditionÂ
Includes an overview of SARS-CoV-2 pathogenesis; the neuroinvasive potential of coronaviruses; proposed mechanisms of CNS invasion with SARS-CoV-2 and possible neuropathological mechanisms; case reports of neurological complications; and recommendations from the European Academy of Neurology.
The following are some of the novelties, oddities and curiosities recently published in the multiple sclerosis literature.
HSCT and COVID-19: There is a new report of four MS patients who were diagnosed with COVID-19 in the 6-31 months after receiving autologous hematopoietic stem cell transplant (Gazca et al. Hematology 2020;25:320). Subjects (3F, 1M) were aged 39-54 years. Three contracted COVID-19 from a family member. Only 1 of 4 patients was hospitalized but did not require an ICU stay. No neurological complications of COVID-19 infection were reported. Read More